

Fuzidova acid belongs to the group of fuzidin, antimicrobial compounds, the mechanism of action of which is associated with impaired protein synthesis in a bacterial cell. By blocking the elongation of factor G, they prevent its binding to ribosomes and guanosine triphosphate, which interrupts the release of the energy required for protein synthesis, and leads to the death of the bacterial cell.
Active against microorganisms that most often cause eye infections:
Enterobacteriaciae and Pseudomonas spp. resistant to fusidic acid.
Pharmacokinetics
The dosage form of the drug (viscous eye drops) provides long-term contact with the conjunctiva and a sufficient concentration of fusidic acid in the tear fluid, provided it is used 2 times / day.
After 1, 3, 6 and 12 hours after a single application of Fucithalmic, the average concentration of fusidic acid in the tear fluid is 15.7; 15.2; 10.5 and 5.6 mcg / ml, respectively. In intraocular fluid, the concentration of fusidic acid, equal to 0.3 μg / ml (after a single application) and 0.8 μg / ml (after repeated use), is reached within 1 h after application and maintained for at least 12 h, while fusidic serum acid is not detected.
Treatment of bacterial infections of the eyes caused by microorganisms sensitive to the drug:
1 g of eye drops contains:
Active ingredients
Excipients
Benzalkonium chloride, disodium edetate, mannitol, carbomer 974P, sodium hydroxide, purified water.
No customer reviews for the moment.
1 drop in the conjunctival sac of the affected eye 2 times / day for 7 days.
In the absence of positive dynamics within 7 days of use of the drug, therapy should be revised using other drugs.
On the part of the organ of vision: in rare cases - allergic reactions (in the form of edema of the follicles of the transitional fold of the conjunctiva and urticaria); itching, burning, conjunctival hyperemia, soreness, tearing, eyelid edema, exacerbation of conjunctivitis.
Fucitalmic should be discontinued if there is evidence of hypersensitivity to the drug.
Hypersensitivity to the drug.
Preservative (benzalkonium chloride) is a potential allergen.
Data on drug interactions are not available.
There is not enough experience with the drug during pregnancy and lactation (breastfeeding). It is possible to use as prescribed by the attending physician, if the expected therapeutic effect exceeds the risk of possible side effects.
The tube must be closed after each use. Do not touch the tip of the eye.
It is not recommended to wear contact lenses during the use of Fuzzitalmika, since its components may cause clouding of the lenses.
Influence on ability to drive motor transport and control mechanisms
When a blurring of vision occurs after instillation, it is necessary to refrain from driving and engaging in potentially hazardous activities that require increased concentration of attention and psychomotor speed, before restoring vision.
Data overdose of the drug is not available.